Obesity drugs in clinical development

Review of anti-obesity drugs in clinical development including centrally-acting agents, peripheral satiety signal targets like GLP-1, and other weight loss mechanisms.

Abstract

A number of anti-obesity drugs are currently undergoing clinical development.. These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1.

Key Findings

These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist A...

Study Design

Research study